Survey on human T-lymphotropic virus infection among blood donors in Hunan province
10.13303/j.cjbt.issn.1004-549x.2025.08.012
- VernacularTitle:湖南省献血者人群人类嗜T淋巴细胞病毒感染情况调查
- Author:
Binbin ZOU
1
;
Qing HU
1
;
Ni SUN
1
;
Xiangmei KANG
1
;
Tingting HU
1
;
Fei FAN
1
;
Feixue ZHAO
1
Author Information
1. Changsha Blood Center, Changsha 410008, China
- Publication Type:Journal Article
- Keywords:
human T-lymphotropic virus (HTLV);
blood donors;
infection;
follow-up
- From:
Chinese Journal of Blood Transfusion
2025;38(8):1077-1082
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the prevalence of human T-lymphotropic virus (HTLV) infection among blood donors in Hunan Province from 2022 to 2024. Methods: A total of 1 830 342 blood donors from 14 prefecture-level blood centers in Hunan Province over the past three years were screened for anti-HTLV-Ⅰ/Ⅱ using enzyme-linked immunosorbent assay (ELISA). Initially reactive samples were further tested with Line Immunoassay (LIA
)/MP-Western blot and RT-PCR nucleic acid test for confirmation. Blood donors confirmed positive for HTLV were tracked and followed up. Results: From 2022 to 2024, the initial ELISA reactive rate for anti-HTLV-I/II among blood donors in Hunan Province was 1.36 per 10 000 (249/1 830 342). The confirmed positive rate was 0.20 per 10 000 (37/1 830 342), accounting for 14.86% of the initially reactive donors. The follow-up success rate for confirmed HTLV-positive blood donors was only 18.92%, while that for HTLV-indeterminate donors was 54.17%. Conclusion: The confirmed HTLV infection rates in Yueyang, Loudi, Shaoyang, Yiyang, and Zhuzhou cities were higher than the provincial (0.20 per 10 000). Chenzhou, Yongzhou, Zhangjiajie, and Xiangxi were identified as low prevalence areas, with an infection rate of 0. The overall follow-up success rate was low, indicating significant difficulties and bottlenecks in follow-up work. The comprehensive screening for HTLV and follow-up studies in Hunan provide valuable data to further improve blood safety testing strategies and risk warning mechanisms.
